Bicara Therapeutics BCAX Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $323.46M-30.0% | $96.69M-80.3% | $171.67M-67.0% | $436.61M+114% | $462.07M+114% | ||
| $216.29M— | $318.12M— | $118.49M— | —— | —— | ||
| $544.92M+15.8% | $422.05M-16.0% | $297.37M-43.0% | $444.39M— | $470.75M— | ||
| $346K+154% | $330K+113% | $135K+3.8% | $117K— | $136K— | ||
| $553.6M+15.8% | $430.99M-15.5% | $424.69M-19.0% | $453.59M— | $478.08M— | ||
| $39.34M+106% | $28.95M+60.9% | $21.03M+45.2% | $17.23M— | $19.12M— | ||
| $39.64M+107% | $29.54M+63.0% | $21.91M+49.9% | $18.39M— | $19.12M— | ||
| 500M0.0% | 500M+7,142,757% | 500M0.0% | 500M— | 500M— | ||
| -$415.18M-61.0% | -$358.97M-62.4% | -$321.58M-60.7% | -$285.25M— | -$257.86M— | ||
| $513.96M+12.0% | $401.45M-18.4% | $402.78M-21.0% | $435.2M+349% | $458.96M+387% | ||
| $553.6M+15.8% | $430.99M-15.5% | $424.69M-19.0% | $453.59M— | $478.08M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Bicara Therapeutics's total assets?
- Bicara Therapeutics (BCAX) holds $553.6M in total assets, up 15.8% year over year.
- How much debt does Bicara Therapeutics have?
- Bicara Therapeutics carries $1.4M in total debt against $514.0M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does Bicara Therapeutics have?
- Bicara Therapeutics holds $323.5M in cash and equivalents.
- Can Bicara Therapeutics cover its short-term obligations?
- Its current ratio is 13.85 — current assets exceed current liabilities.
- Where does Bicara Therapeutics's balance sheet data come from?
- Every line is extracted from Bicara Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.